default author photo

James Gulley

National Institutes of Health (NIH) - Clinical Immunotherapy Section

9000 Rockville Pike

Bethesda, MD 20892

United States

SCHOLARLY PAPERS

3

DOWNLOADS

275

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Final Results from a Phase 1 Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or with Ipilimumab for Advanced/Metastatic Genitourinary Tumours

Number of pages: 73 Posted: 26 Jun 2023
National Institutes of Health (NIH) - Bladder Cancer Section, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Biostatistics and Data Management Section, National Institutes of Health - Developmental Therapeutics Branch, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Laboratory of Translational Genomics, Government of the United States of America - Center for Cancer Research, National Institutes of Health (NIH) - Laboratory of Pathology, Government of the United States of America - Laboratory of Pathology, Government of the United States of America - Laboratory of Pathology, Government of the United States of America - Clinical Center, Government of the United States of America - Clinical Center, Government of the United States of America - Center for Cancer Research, Government of the United States of America - Urologic Oncology Branch, Government of the United States of America - Urologic Oncology Branch, Government of the United States of America - Urologic Oncology Branch, Government of the United States of America - Urologic Oncology Branch, Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, Government of the United States of America - Division of Cancer Prevention, National Institutes of Health (NIH) - Clinical Immunotherapy Section, Rutgers University, New Brunswick - Rutgers Cancer Institute of New Jersey, City of Hope - Comprehensive Cancer Center, University of Southern California, Columbia University - Herbert Irving Comprehensive Cancer Center, University of California, Davis - Comprehensive Cancer Center, Government of the United States of America - Center for Cancer Research and Ohio State University (OSU) - Department of Internal Medicine
Downloads 114 (621,896)

Abstract:

Loading...

Urothelial Carcinoma, Rare Genitourinary Tumours, Immunotherapy, Immune Correlates Of Antitumor Response, Renal Medullary Carcinoma, Bladder Squamous Cell Carcinoma, Squamous Cell Carcinoma Of The Penis, Bladder Adenocarcinoma, Urachal Carcinoma, Cabozantinib

2.

HLA-A*03 is a Predictive Biomarker of Poor Response to Immune Checkpoint Blockade in Cancer

Number of pages: 26 Posted: 06 May 2021
University of Oxford - Nuffield Department of Medicine, Government of the United States of America - Frederick National Laboratory for Cancer Research, Government of the United States of America - Laboratory of Translational Genomics, Harvard University - Division of Population Sciences, Harvard University - Massachusetts General Hospital, Harvard University - Lank Center for Genitourinary Oncology, Harvard University - Massachusetts General Hospital, Government of the United States of America - Frederick National Laboratory for Cancer Research, EMD Serono Research & Development Institute - Bioinformatics, Department of Translational Medicine, Harvard University - Dana-Farber Cancer Institute, Bristol Myers Squibb, Pfizer, Inc. - Computational Biology, Pfizer, Inc. - Translational Oncology, Harvard University - Division of Population Sciences, Harvard University - Lank Center for Genitourinary Oncology, National Institutes of Health (NIH) - Clinical Immunotherapy Section and National Cancer Institute - Basic Science Program
Downloads 113 (626,371)

Abstract:

Loading...

3.

MPA PASS Enables Stitched Multiplex Multi-Dimensional EV Repertoire Analysis

Number of pages: 33 Posted: 12 Feb 2021
National Institutes of Health (NIH) - Translational Nanobiology Section, National Institutes of Health (NIH) - Translational Nanobiology Section, National Institutes of Health (NIH) - Translational Nanobiology Section, National Institutes of Health (NIH) - Translational Nanobiology Section, National Institutes of Health (NIH) - Translational Nanobiology Section, National Institutes of Health (NIH) - Translational Nanobiology Section, National Institutes of Health (NIH) - Clinical Immunotherapy Section, National Institutes of Health - Developmental Therapeutics Branch, National Institutes of Health (NIH) - Vaccine Branch, National Institutes of Health (NIH) - Viral Immunology Section, National Institutes of Health (NIH) - Viral Immunology Section, Karolinska Institutet - Clinical Research Center, University Medical Center Hamburg-Eppendorf - Department of Neurosurgery, University Medical Center Hamburg-Eppendorf - Department of Neurosurgery, University Medical Center Hamburg-Eppendorf - Department of Neurosurgery, National Institutes of Health (NIH) - Laboratory of Pathology, National Institutes of Health, National Cancer Institute - Urologic Oncology Branch, Government of the United States of America - Gastrointestinal and Thoracic Malignancy Section, Ben-Gurion University of the Negev - The Shraga Segal Department of Microbiology, Immunology and Genetics, National Institutes of Health (NIH) - Laboratory of Human Carcinogenesis, National Institutes of Health (NIH) - Bladder Cancer Section, Tulane University - Department of Urology, Northeastern University - Barnett Institute of Chemical and Biological Analysis, National Institutes of Health - Developmental Therapeutics Branch, Baylor College of Medicine - Department of Molecular and Human Genetics, PSL Research University - Institut Curie Centre de Recherche, Baylor College of Medicine - Department of Molecular and Human Genetics, PSL Research University - Institut Curie Centre de Recherche, National Institutes of Health (NIH) - Comparative Oncology Program, National Institutes of Health (NIH) - Vaccine Branch, National Institutes of Health - Cancer Data Science Laboratory, National Cancer Institute - Laboratory of Pathology, National Institutes of Health (NIH) - Radiation Oncology Branch, National Institutes of Health (NIH) - Clinical Immunotherapy Section, Harvard Medical School - Department of Medicine, National Institutes of Health (NIH) - Viral Immunology Section and National Institutes of Health (NIH) - Translational Nanobiology Section
Downloads 48 (1,086,013)

Abstract:

Loading...